Ticker > Company >

Vaishali Pharma share price

Vaishali Pharma Ltd.

NSE: VAISHALI SECTOR: Trading  40.18 K   47   3

7.92
+0.02 (0.25%)
NSE: 12 Dec 03:58 PM

Price Summary

Today's High

₹ 8.1

Today's Low

₹ 7.8

52 Week High

₹ 20.1

52 Week Low

₹ 7.75

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

103.33 Cr.

Enterprise Value

113.14 Cr.

No. of Shares

13.05 Cr.

P/E

0

P/B

1.53

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  5.16

CASH

1.84 Cr.

DEBT

11.66 Cr.

Promoter Holding

26.32 %

EPS (TTM)

₹  -0.03

Sales Growth

14.77%

ROE

1.62 %

ROCE

4.99%

Profit Growth

13.7 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year14.77%
3 Year9.31%
5 Year10.51%

Profit Growth

1 Year13.7%
3 Year-41.21%
5 Year90.26%

ROE%

1 Year1.62%
3 Year8.66%
5 Year9.45%

ROCE %

1 Year4.99%
3 Year10.91%
5 Year12.39%

Debt/Equity

0.1796

Price to Cash Flow

-5.73

Interest Cover Ratio

1.593

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2025 26.32 0.00
Jun 2025 26.32 0.00
Mar 2025 26.32 0.00
Dec 2024 26.32 0.00
Sep 2024 26.32 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 87.6309 days.
  • Company has a healthy liquidity position with current ratio of 2.6086.

 Limitations

  • The company has shown a poor profit growth of -41.2145725958559% for the Past 3 years.
  • The company has shown a poor revenue growth of 9.30817753390596% for the Past 3 years.
  • Company has negative cash flow from operations of -18.0383.
  • The company is trading at a high PE of 0.
  • The company is trading at a high EV/EBITDA of 63.9308.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
Net Sales 20.79 27.91 32.25 23.75 33.45
Total Expenditure 18.37 26.55 38.29 22.38 32.06
Operating Profit 2.42 1.37 -6.04 1.37 1.39
Other Income 0.71 1.07 1 0.84 0.84
Interest 0.38 0.38 0.44 0.33 0.4
Depreciation 0.12 0.12 0.12 0.14 0.17
Exceptional Items 0 0 0 0 0
Profit Before Tax 2.63 1.93 -5.6 1.74 1.66
Tax 0.66 0.49 -1.31 0.46 0.47
Profit After Tax 1.97 1.44 -4.29 1.28 1.18
Adjusted EPS (Rs) 0.15 0.22 -0.33 0.1 0.09

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 53.77 75.82 69.66 86.28 99.03
Total Expenditure 51.13 68.94 60.28 84.61 98.45
Operating Profit 2.65 6.89 9.38 1.67 0.57
Other Income 1.81 1.79 2.23 2.03 3.21
Interest 2.63 2.49 2.26 2.27 2.07
Depreciation 0.43 0.46 0.5 0.51 0.49
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.4 5.73 8.85 0.93 1.23
Tax 0.36 1.7 2.24 0.21 0.41
Net Profit 1.05 4.02 6.6 0.72 0.82
Adjusted EPS (Rs.) 0.1 0.38 0.63 0.07 0.06

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 10.55 10.55 10.55 10.72 26.09
Total Reserves 11.87 15.81 29.99 32.12 38.82
Borrowings 4.03 3.11 5.23 3.6 4.2
Other N/C liabilities 0.26 0.07 0.93 0.26 0.5
Current liabilities 59.26 51.94 32.07 33.08 40.05
Total Liabilities 85.98 81.46 78.75 79.78 109.66
Assets
Net Block 1.22 1.18 1.98 1.52 1.83
Capital WIP 0 0 0 0 0
Intangible WIP 0.05 0.49 0.67 0.74 0.25
Investments 0.43 0.43 0.43 0.43 0.43
Loans & Advances 0.96 1.43 1.43 0.93 0.93
Other N/C Assets 2.03 1.5 1.56 1.64 1.73
Current Assets 81.3 76.43 72.67 74.52 104.48
Total Assets 85.98 81.46 78.75 79.78 109.66
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 1.4 5.73 8.85 0.93 1.23
Adjustment 3.45 1.62 1.16 5.85 6.91
Changes in Assets & Liabilities -2.78 -5.2 -7.36 -3.7 -25.82
Tax Paid -0.06 -0.83 -1.56 -2.28 -0.35
Operating Cash Flow 2.01 1.32 1.08 0.81 -18.04
Investing Cash Flow -0.11 -0.85 0.28 1.2 -0.19
Financing Cash Flow -1.81 0.42 -1.73 -1.42 18.49
Net Cash Flow 0.09 0.89 -0.37 0.59 0.26

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
promoters 26.32 26.32 26.32 26.32 26.32
atul arvindbhai vasani 21.10 21.10 21.10 21.10 21.10
bharti kiritkumar tolia 0.67 0.67 0.67 0.67 0.67
jagruti atul vasani 4.48 4.48 4.48 4.48 4.48
punita kaushik gandhi 0.04 0.04 0.04 0.04 0.04
vaishali a vasani 0.03 0.03 0.03 0.03 0.03
PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
investors 73.68 73.68 73.68 73.68 73.68
bipinbhai devabhai raval - - - - 1.57
kabra priya - - - - 1.15
krishna awtar kabra 1.22 1.22 1.24 1.24 1.24
nupur anil shah 6.15 4.91 5.36 5.09 5.49
renu pittie 2.33 2.26 2.26 2.26 2.26
sapan anil shah 8.04 6.82 7.05 6.63 6.39
shah nishant - - - - 1.06
sawaca business machines ... 1.39 1.38 1.38 1.38 -
nishant pitti - 2.46 2.89 - -

Annual Reports

Title Link
Title Link
 No Annual reports exist for this company.Report us

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit and Research reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation and Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Vaishali Pharma - Quaterly Results 11 Aug, 6:14 PM Vaishali Pharma - Quaterly Results 11 Aug, 6:14 PM Vaishali Pharma - Quaterly Results 11 Aug, 6:14 PM Vaishali Pharma - Quaterly Results 6 Feb, 5:39 PM Vaishali Pharma - Quaterly Results 6 Feb, 5:39 PM Vaishali Pharma - Quaterly Results 6 Feb, 5:39 PM Vaishali Pharma - Quaterly Results 14 Aug, 8:04 PM Vaishali Pharma - Quaterly Results 14 Aug, 8:04 PM Vaishali Pharma - Quaterly Results 30 May, 12:00 PM Vaishali Pharma - Quaterly Results 2 Feb, 12:00 PM Vaishali Pharma - Quaterly Results 2 Feb, 12:00 PM Vaishali Pharma - Quaterly Results 2 Feb, 12:00 PM Vaishali Pharma bags order from African Continent 28 Nov, 11:40 AM Vaishali Pharma - Quaterly Results 7 Aug, 12:00 PM Vaishali Pharma - Quaterly Results 7 Aug, 12:00 PM Vaishali Pharma - Quaterly Results 7 Aug, 12:00 PM Vaishali Pharma - Quaterly Results 22 May, 12:00 PM Vaishali Pharma - Quaterly Results 22 May, 12:00 PM Vaishali Pharma - Quaterly Results 22 May, 12:00 PM Vaishali Pharma bags order worth $73.85 million 28 Feb, 2:50 PM Vaishali Pharma - Quaterly Results 6 Feb, 12:00 PM Vaishali Pharma - Quaterly Results 6 Feb, 12:00 PM Vaishali Pharma - Quaterly Results 6 Feb, 12:00 PM Vaishali Pharma, Jark Pharma enter into partnership 21 Dec, 2:25 PM Vaishali Pharma - Quaterly Results 3 Nov, 12:00 PM Vaishali Pharma - Quaterly Results 3 Nov, 12:00 PM Vaishali Pharma - Quaterly Results 3 Nov, 12:00 PM Vaishali Pharma - Quaterly Results 25 Jul, 12:00 PM Vaishali Pharma - Quaterly Results 25 Jul, 12:00 PM Vaishali Pharma partners with Sankalp LifeCare 19 Apr, 3:09 PM Vaishali Pharma - Quaterly Results 21 Jan, 12:00 PM Vaishali Pharma bags orders from Nicaragua, Madagascar 28 Jun, 11:09 AM Vaishali Pharma receives order in excess of $100,000 from Russia 22 Jun, 11:08 AM Vaishali Pharma launches series of Immunity booster products 14 Jun, 11:05 AM Vaishali Pharma bags order worth $270,000 from Afghanistan 22 Apr, 11:17 AM Vaishali Pharma initiates registration of 30 products in Central African Countries 16 Apr, 10:43 AM Vaishali Pharma bags yet another bulk order of Rs 32.00 crore 14 Jan, 11:22 AM Vaishali Pharma enters into licensing agreement with U.S.A. Healthcare market 4 Jan, 11:40 AM Vaishali Pharma successfully delivers large bulk order worth Rs 16 crore 1 Jan, 5:07 PM Vaishali Pharma gets approval, registration for five new products 31 Dec, 10:45 AM Vaishali Pharma secures first Bulk order worth Rs 16.00 crore 29 Dec, 10:45 AM Vaishali Pharma launches personal care, hygiene products 29 Apr, 3:06 PM

Vaishali Pharma Stock Price Analysis and Quick Research Report. Is Vaishali Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Vaishali Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Vaishali Pharma has a PE ratio of -268.474576271186 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Vaishali Pharma has ROA of 0.863% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Vaishali Pharma has a Current ratio of 2.6086.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Vaishali Pharma has a ROE of 1.6229%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Vaishali Pharma has a Debt to Equity ratio of 0.1796 which means that the company has low proportion of debt in its capital.

  • Sales growth: Vaishali Pharma has reported revenue growth of 14.7728% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Vaishali Pharma for the current financial year is 0.579648090998689%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Vaishali Pharma is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Vaishali Pharma is Rs -0.0295. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Vaishali Pharma in Ticker for free. Also, one can get the intrinsic value of Vaishali Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Vaishali Pharma FAQs

Q1. What is Vaishali Pharma share price today?
Ans: The current share price of Vaishali Pharma is Rs 7.92.

Q2. What is the market capitalisation of Vaishali Pharma?
Ans: Vaishali Pharma has a market capitalisation of Rs 103.32600696 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Vaishali Pharma?
Ans: The PE ratio of Vaishali Pharma is -268.474576271186 and the P/B ratio of Vaishali Pharma is 1.53348694019014, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Vaishali Pharma share?
Ans: The 52-week high share price of Vaishali Pharma is Rs 20.1, and the 52-week low share price of Vaishali Pharma is Rs 7.75.

Q5. Does Vaishali Pharma pay dividends?
Ans: Currently, Vaishali Pharma does not pay dividends. Dividend yield of Vaishali Pharma is around 0%.

Q6. What are the face value and book value of Vaishali Pharma shares?
Ans: The face value of Vaishali Pharma shares is Rs 2, while the book value per share of Vaishali Pharma is around Rs 5.1647. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Vaishali Pharma?
Ans: Vaishali Pharma has a total debt of Rs 11.6592 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Vaishali Pharma?
Ans: The ROE of Vaishali Pharma is 1.6229% and ROCE of Vaishali Pharma is 4.9882%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Vaishali Pharma a good buy for the long term?
Ans: The Vaishali Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Vaishali Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Vaishali Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Vaishali Pharma’s financials?
Ans: You can review Vaishali Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Vaishali Pharma
X